Transforming growth factor-β1 promotes breast cancer metastasis by downregulating miR-196a-3p expression

Yan Chen1,2,*, Shai Huang2,*, Bo Wu3,*, Jiankai Fang2, Minsheng Zhu2, Li Sun4, Lifeng Zhang1, Yongsheng Zhang5, Maomin Sun4, Lingling Guo2 and Shouli Wang2,6,7

1Department of Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, China
2Department of Pathology, School of Biology & Basic Medical Sciences, Soochow University, Suzhou 215123, China
3Department of Surgery, The People's Hospital of Sihong County, Sihong 223900, Jiangsu Province, China
4Laboratory Animal Research Center, Soochow University School of Medicine, Suzhou 215123, China
5Department of Pathology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China
6Laboratory of Molecular Pathology, Soochow University & Sihong County People's Hospital, Suzhou 215123, China
7Suzhou Key Laboratory of Tumor Microenvironment and Pathology, Soochow University, Suzhou 215006, China

*These authors have contributed equally to this work

Correspondence to: Shouli Wang, email: wangsoly12@hotmail.com
Lingling Guo, email: guo-lingling@126.com

Keywords: microRNA, miR-196a-3p, transforming growth factor-β1, breast cancer

Received: December 12, 2016 Accepted: February 23, 2017 Published: March 17, 2017

Copyright: Chen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Transforming growth factor-β1 is considered a key contributor to the progression of breast cancer. MicroRNAs are important factors in the development and progression of many malignancies. In the present study, upon studies of breast cancer cell lines and tissues, we showed that microRNA -196a-3p is decreased by transforming growth factor-β1 in breast cancer cells and associated with breast cancer progression. We identified neuropilin-2 as a target gene of microRNA -196a-3p and showed that it is regulated by transforming growth factor-β1. Moreover, transforming growth factor-β1-mediated inhibition of microRNA -196a-3p and activation of neuropilin-2 were required for transforming growth factor-β1-induced migration and invasion of breast cancer cells. In addition, neuropilin-2 expression was suppressed in breast tumors, particularly in triple-negative breast cancers. Collectively, our findings strongly indicate that microRNA -196a-3p is a predictive biomarker of breast cancer metastasis and patient survival and a potential therapeutic target in metastatic breast cancer.

INTRODUCTION

Despite considerable progress in the early diagnosis and surgical therapy of breast cancers, breast cancer is the second leading cause of death in the United States [1], and the first cause of cancer-related death in women younger than 45 years followed by lung cancer in China [2]. Transforming growth factor-β1 (TGF-β1) is considered a key contributor to the progression of breast cancer [3, 4]; TGF-β1 signaling features a growth inhibitory effect at an early stage of breast cancer cells, but aggressive oncogenic activity at the advanced malignant state [5-7]. Recent results indicate an association between TGF-β1 signaling and microRNAs (miRNAs, miR), as revealed by our previous studies in rhabdomyosarcoma [8, 9] and those of others about breast cancers [4, 10-13], providing new insight into the nature of cancer.

MiRNAs, which are noncoding RNAs that regulate target gene expression post-transcriptionally, show unbalanced expression in cancers [14], and there is increasing evidence of the efficacy of miRNA-based therapies [15]. Considering that TGF-β1 promotes the progression of breast cancer at advanced stages [3, 4], we assumed that miRNA expression inhibited by
TGF-β1 must have antitumor potential, as previously demonstrated for miR-450b-5p [8] and miR-411-5p [9]. Using TGF-β1 knockdown colorectal cancer cells (HT-29, SW620 and LoVo) and comprehensive locked nucleic acid microarray analyses, five significantly raised miRNAs were selected (Tracking Number: GSE53338, unpublished data), and their expression was examined in breast cancer. We found that TGF-β1 suppressed miR-196a-3p in colorectal cancer and in breast cancer and exerted an antitumor effect on breast cancer.

In the present study, we showed that ectopic overexpression of miR-196a-3p reversed TGF-β-induced breast cancer cell migration and invasion. We also identified the protein neuropilin 2 (NRP2) as a downstream target of miR-196a-3p, and showed that blocking NRP2 expression potently antagonized TGF-β promigratory effects in invasive breast cancer cells. Collectively, our results demonstrate that miR-196a-3p and its downstream target NRP2 are involved in TGF-β-induced cell migration and invasion in invasive breast cancer cells, suggesting that restoring the expression of miR-196a-3p is a potential therapeutic approach for the treatment of breast cancer.

RESULTS

miR-196a-3p expression is reduced in breast cancer in correlation with metastatic potential

In a previous study, we identified five TGF-β1 inhibited miRNAs in colorectal cancer by microarray analysis (GSE53338), including miR-4313, miR-3691-3p, miR-196a-3p, miR-324-3p, and miR-4723-3p. To investigate whether these miRNAs are correlated with the malignant behavior of breast cancer, we examined the expression of these miRNAs in two different breast cancer cell lines (the noninvasive luminal cell line MCF-7 and the highly invasive cell line MDA-MB-231) by reverse transcription-polymerase chain reaction (RT-PCR). We found that only miR-196a-3p was markedly decreased in MDA-MB-231 cells (Figure 1A). To further verify the relationship between miR-196a-3p expression and the malignant behavior of breast cancer, three...
noninvasive breast cancer cell lines (MCF-7, T-47D, and SK-BR-3) and two highly invasive breast cancer cell lines (BT-549 and MDA-MB-231) were analyzed. We found that miR-196a-3p was inhibited by TGF-β1 in all tested breast cancer cell lines, and the expression of miR-196a-3p was higher in noninvasive breast cancer cell lines than in the two highly invasive breast cancer cell lines (Figure 1B).

We then detected miR-196a-3p expression levels in 13 primary tumors and 11 non-cancerous specimens. As shown in Figure 1C, miR-196a-3p was declined by approximately two-fold in tumors compared with non-cancerous specimens. Moreover, miR-196a-3p expression was lower in basal like breast cancer than in the other subtypes of breast cancer (Figure 1D). Taken together, these results suggest that miR-196a-3p plays an important role downstream of TGF-β-signal transduction in breast cancer.

**Decreased expression of miR-196a-3p correlates with poor clinical outcomes in breast cancer**

The expression of miR-196a-3p was examined using real-time qRT-PCR in 112 breast cancer tissue samples and the association of miR-196a-3p expression levels with clinicopathological features was analyzed. As shown in Table 1, low miR-196a-3p expression levels were closely correlated with lymph node metastasis ($p=0.008$), TNM stage ($p=0.001$), and pathological differentiation ($p=0.029$). However, no significant correlations between

| Parameters                     | miR-196a-3p expression | $P$ value |
|--------------------------------|------------------------|-----------|
|                                | Low (52)               | High (60) |
| Age (years)                    |                        |           |
| $<50$                          | 18                     | 31        | 0.07     |
| $\geq 50$                      | 34                     | 29        |          |
| Tumor size (cm)                |                        |           |
| $<2$                           | 25                     | 38        | 0.105    |
| $\geq 2$                       | 27                     | 22        |          |
| TNM stage                      |                        |           |
| I+II                           | 24                     | 46        | 0.001*   |
| III                            | 28                     | 14        |          |
| Differentiation grade          |                        |           |
| G1+G2                          | 34                     | 50        | 0.029*   |
| G3                             | 18                     | 10        |          |
| Lymph node metastasis          |                        |           |
| Yes                            | 33                     | 23        | 0.008*   |
| No                             | 19                     | 37        |          |
| ER status                      |                        |           |
| Negative                       | 32                     | 26        | 0.054    |
| Positive                       | 20                     | 34        |          |
| PR status                      |                        |           |
| Negative                       | 30                     | 27        | 0.18     |
| Positive                       | 22                     | 33        |          |
| HER2 status                    |                        |           |
| Negative                       | 31                     | 26        | 0.086    |
| Positive                       | 21                     | 34        |          |

* $P < 0.05$ was considered significant.

### Table 1: Relationship between miR-196a-3p expression and clinical-pathologic variables of breast cancer patients
miR-196a-3p expression and age, tumor size, estrogen receptor (ER) status, progesterone receptor (PR) status and human epidermal growth factor receptor 2 (HER2) status were found. Our results indicate that miR-196a-3p may play a critical part in the carcinogenesis and progression of breast cancer.

To further investigate the significance of miR-196a-3p in terms of clinical prognosis, the Kaplan–Meier method and log-rank test were used to evaluate the differences in overall survival and disease-free survival between the low-expression group and the high-expression group. As shown in Figure 2, the 5-year overall survival of the low-miR-196a-3p expression group was significantly shorter than that of the high-miR-196a-3p expression group (log rank test, \( p = 0.0019 \)). Moreover, patients with low expression of miR-196a-3p had significantly shorter disease-free survival than patients with high miR-196a-3p expression (log rank test, \( p = 0.0063 \)). These results indicated that inhibition of miR-196a-3p expression may be correlated with poor survival in breast cancer patients.

miR-196a-3p suppresses TGF-β-mediated migration and invasion

TGF-β1 was shown to promote cellular migration and invasion in human breast cancer cells [16-18]. To investigate whether TGF-β1-inhibited miR-196a-3p bearing effect of anti-tumor on breast cancer, we tested miR-196a-3p-mimics. Transient transfection of 80 nM mimic into MDA-MB-231 cells resulted in an approximately 60-fold increase of miR-196a-3p (Figure 3A). Cell migration and invasion were assessed by the Transwell assay in MDA-MB-231 cells transfected with the miR-196a-3p mimic or a scrambled mimic as a negative control and stimulated with or without TGF-β. The number of cells migrated through the Transwell was calculated after 24 h. As shown in Figure 3B, TGF-β induced MDA-MB-231 cell migration and invasion in the mock and control groups, whereas the overexpression miR-196a-3p did not affect the proliferative properties of breast cancer cells as determined by the MTT assay (Supplementary Figure 1).

NRP2 is the target gene of miR-196a-3p and is regulated by TGF-β1

Bioinformatics analyses using various algorithms such as DIANA, MICRORNA.OR, and MIRDB identified the top four potential predicted targets for miR-196a-3p (Figure 4A). Only two target genes, ZNF280B and NRP2, were increased in response to TGF-β stimulation (Figure 4B). To investigate whether the TGF-β-mediated activation of ZNF280B and NRP2 was miR-196a-3p-dependent, we examined the effect TGF-β stimulation on the levels of ZNF280B and NRP2 in MDA-MB-231 cells transfected with or without the miR-196a-3p mimic. The results showed that the miR-196a-3p mimic had no effect on ZNF280B levels, whereas it significantly inhibited the expression of NRP2 and reversed the effect of TGF-β1 on the expression of NRP2 (Figure 4C).

Moreover, transient transfection of a NRP2-3′-UTR-luciferase reporter into MDA-MB-231 cells stably expressing miR-196a-3p showed that miR-196a-3p decreased luciferase activity in the NRP2-3′-UTR construct. Importantly, mutation of the miR-196a-3p seed sequence located within the NRP2-3′-UTR prevented miR-196a-3p from suppressing luciferase expression in MDA-MB-231 cells (Figure 4D). These results indicated that miR-196a-3p inhibits NRP2

![Figure 2: Decreased expression of miR-196a-3p correlates with poor clinical outcomes in breast cancer.](link)

The overall survival (OS) (left) and disease-free survival (DFS) (right) curves for the studied patients with high or low miR-196a-3p expression, \(*p < 0.01\).
Figure 3: miR-196a-3p suppresses TGF-β1-mediated migration and invasion in breast cancer. (A) qRT-PCR analysis of miR-196a-3p levels in MDA-MB-231 cells transfected with 80 nM mimic. The results are means of three independent experiments ± S.D. (**) p < 0.01. (B) MDA-MB-231 cells were transfected with 80 nM miR-196a-3p mimic. The migratory and invasive behavior was measured at 24 h after stimulation with 5 ng/ml TGF-β1. (miR-196a-3p-M: miR-196a-3p-mimics; Scrambled M: Scrambled mimics; Con: Control) The results are means of three independent experiments ± S.D. (*p < 0.05, **p < 0.01, ***p < 0.001).
expression by binding to its complementary seed sequence in the NRP2-3′-UTR, suggesting that NRP2 is a target gene of miR-196a-3p and is controlled by the TGF-β1 signaling pathway.

**NRP2 promotes TGF-β-mediated migration and invasion**

To investigate whether NRP2 expression is required for TGF-β-mediated cell migration and invasion, NRP2 was silenced using an siRNA specific to human NRP2 (Supplementary Figure 2). Knockdown of NRP2 expression significantly inhibited TGF-β1-induced migration (Figure 5A,) and invasion (Figure 5B) of MDA-MB-231 cells. The effects of the NRP2 siRNA on the viability of breast cancer cells was examined using the MTT assay, which showed that NRP2 silencing did not change the proliferative properties of the cells (Supplementary Figure 3), consistent with effect of the miR-196a-3p mimic. These results indicate that miR-196a-3p and NRP2 are involved the same pathway downstream of TGF-β to manipulate cellular migration and invasion in breast cancer cells.
miR-196a-3p inhibits the proliferation and metastasis of MDA-MB-231 cells in vivo

The mammary fat pads of nude mice were inoculated in situ with MDA-MB-231 cells. When the xenograft tumors reached 50 mm³, miR-196a-3p and control agomir were injected into the tumors (1 nmol/injection, once every 2 days). Mice were sacrificed at 24 days after the first injection. As shown in Figure 6A, both the volume and weight of tumors were significantly lower in miR-196a-3p-mimic treated groups than in control groups. To investigate the effect of miR-196a-3p on the metastasis of breast cancer cells, MDA-MB-231 cells were randomly injected into nude mice via the tail vein, followed by administration of miR-196a-3p and control agomir. Metastatic nodules were observed on the surface of the lungs in mice injected with control agomir, whereas no nodules were found in mice injected with miR-196a-3p agomir (Figure 6B). Immunostaining analysis showed that miR-196a-3p inhibited ki-67 expression and NRP2 expression (Figure 6C). These data indicated that miR-196a-3p inhibited the metastasis of MDA-MB-231 cells by targeting NRP2 in vivo.

NRP2 expression is negatively related to the expression of miR-196a-3p in breast cancers, especially in triple-negative breast cancer(TNBC)

NRP2 protein levels were examined by immunostaining and comprising 10 cases of paired non-tumor and primary breast cancer tissues. The results showed that higher levels NRP2 in membrane and cytoplasmic was detected in all primary breast cancer tissues than in nontumor (Figure 7A). In addition, the level of NRP2 expression was negatively related to the expression of miR-196a-3p in breast cancers, especially in TNBC (Figure 7B). These results provided additional evidence supporting the theory that NRP2 acts downstream of miR-196a-3p in breast cancers.

Figure 5: NRP2 promotes TGF-β1-mediated migration and invasion. MDA-MB-231 cells were transfected with 80 nm NRP2 siRNA and siRNA negative controls, the migratory (A) and invasive (B) behaviors were measured at 24 h after stimulation with 5 ng/ml TGF-β1 The results are means of three independent experiments ± S.D. (***p < 0.001). (Con: Control).
Figure 6: miR-196a-3p inhibits the proliferation and metastasis of MDA-MB-231 cells in vivo. (A) Nude mice were challenged in the mammary fat with MDA-MB-231 cells to form xenograft tumors, and miR-196a-3p or control agomir was injected into the tumors. Tumor volumes and weights were monitored. ns: nonsignificance, \( p = 0.1662 \). (B) MDA-MB-231 cells were randomly injected into nude mice via tail vein, followed by administration of miR-196a-3p or control agomir. Metastatic nodules in the lung were observed. Representative lungs were photographed and HE staining of lungs was performed. The results are means of three independent experiments ± S.D. (**\( p < 0.01 \)). (C) Immunohistochemical staining of Ki67 and NRP2 in xenograft tumor tissues. **\( p < 0.01 \) (×200). (miR-196a-3p-A: miR-196a-3p-agomir; Con-A: Control agomir)
DISCUSSION

Metastasis is the primary cause of breast cancer mortality [19, 20], and miRNAs are involved in regulating the behavior of tumor metastasis [21, 22]. Here, we proposed a model in which TGF-β is capable of inducing tumorigenic through the reduction of miR-196a-3p, which targets NRP2, leading to its accumulation (Figure 8), providing novel potential targets for the treatment of metastatic breast cancers.

It is well established that TGF-β has a great deal of significance in the progression of breast cancer [3, 23]. Recently, microRNAs were involved in multiple TGF-β-mediated processes that eventually lead to tumor metastasis [10]. Based on our previous finding that TGF-β1-related miRNAs contribute to tumor progression

![Image](https://example.com/image1)

**Figure 7:** NRP2 expression is negatively related to the expression of miR-196a-3p in breast cancers. (A) NRP2 immunostaining of primary tumors and corresponding non-tumor tissues (Left, ×100; Right, ×200). (B) NRP2 expression in 12 different kinds of breast cancers was measured by qRT-PCR. (3 luminal A, 3 luminal B, 3 ERBB2 overexpressing, and 3 basal-like cases). The results are means of three independent experiments ± S.D. (*p<0.05, **p< 0.01).

![Image](https://example.com/image2)

**Figure 8.** Proposed model of the role of miR-196a-3p in TGF-β-induced cell migration mediated by targeting NRP2 in breast cancer.
We explored TGF-β1 inhibited miRNAs in colorectal cancer cells, including miR-4313, miR-3691-3p, miR-196a-3p, miR-324-3p, and miR-4723-3p, and demonstrated that only miR-196a-3p was restrained in breast cancer lines. Furthermore, miR-196a-3p expression was lower in breast cancer tissues than in adjacent normal breast tissues and associated with lymph node-metastasis, clinical stage, and pathological differentiation. We thus propose that blocking miR-196a-3p expression may be a prerequisite to TGF-β-mediated migration and invasion, as assessed by Transwell assays.

Reports on miR-196a-3p function are rare. Here, to determine the mechanism underlying the antisemetic activity of miR-196a-3p, we selected four potential targets using available online algorithms, and only two target genes were affected under the stimulation of TGF-β1. Based on the mRNA and protein expression of the two candidate target genes in response to miR-196a-3p mimics, we focused on NRP2 as a target gene of miR-196a-3p in breast cancer. NRP2 expression was silenced using a specific siRNA, which inhibited TGF-β-mediated migration and invasion, as shown in Figure 5. This suggested that NRP2 expression modulated by miR-196a-3p has an effect in influencing specific steps in the metastatic cascade. Based on our finding that miR-196a-3p mimics inhibit the metastasis of breast cancer cells, which was reinforced by knockdown of NRP2 and antagonized by TGF-β1 stimulation, and previous reports that NRP2 acts as an oncogene to promote metastasis in cancers such as breast cancer [25], esophageal squamous cell carcinoma [26], and melanoma [27], we hypothesized that miR-196a-3p and its downstream target NRP2 is involved in TGF-β-induced cell migration and invasion in breast cancer. The present study provides evidence confirming the crosstalk between the TGF-β signaling pathway and miRNAs in breast cancer.

The multifunctional cytokine TGF-β1 has a direct influence on breast cancer progression. In the early stages of breast cancer, TGF-β1 inhibits epithelial cell cycle progression and shows tumor suppressive effects. However, in the late stages, TGF-β1 is linked with increased tumor progression and metastasis [3]. Although several studies showed crosstalk between TGF-β1 signaling and miRNAs in breast cancer [4, 10], the role of TGF-β1 signaling in breast cancer remains unclear. Many effects of TGF-β1 on the progression of breast cancer remain undetermined, such as epithelial-to-mesenchymal transition [28, 29], the crucial function of TGF-β1 as a modulator of matrix metalloproteinases [6, 30], and TGF-β1 mediated recruitment of tumor microenvironment [24, 31]. The relationship between the TGF-β signaling pathway and miRNAs should be explored further in clinical studies.

Recently, there are studies found that miR-196 can promote tumor invasion and proliferation through different signaling pathways in a variety of tumors [32, 33], and it is becoming an emerging cancer biomarker for digestive tract cancers [34]. Furthermore, the NRP2 can promotes tumourigenicity and metastasis in oesophageal squamous cell carcinoma through ERK–MAPK–ETV4–MMP–E-cadherin deregulation [26] and it is uniquely support TGF-β-mediated progression in lung cancer [35]. All of which laid the foundation for the specific molecular mechanism of TGFβ1-miRNA-NRP2 this axis for promoting breast cancer metastasis, and provide an important molecular target for breast cancer treatment.

MATERIALS AND METHODS

Cell lines and cell culture

The human breast cancer cell lines MCF-7, T47D, SK-BR3, BT-549 and MDA-MB-231 were obtained from American Type Culture Collection (ATCC; Manassas, VA, USA). MCF-7 and BT-549 cells were cultured in RPMI-1640 medium. T47D, SK-BR3, and MDA-MB-231 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM). Both culture media were supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 units/ml penicillin, and 100 μg/ml streptomycin. The cells were cultured at 37°C in a humidified atmosphere containing 5% CO₂.

Patients and tissue samples

A total of 112 breast cancer tissues and corresponding noncancerous breast tissues were collected directly from surgery after removal of the necessary amount of tissue for routine pathology examination at the Department of Pathology, Second Affiliated Hospital of Soochow University, between 2008 and 2014. The tissues were immediately frozen in liquid nitrogen after surgical removal and stored at −80°C until use. None of these patients had received radiotherapy or chemotherapy prior to surgery. All the specimens were diagnosed by pathologists. Informed written consent was obtained from all patients. Patients’ clinical information was stored in a database and summarized in Table 1.

Bioinformatics search

Potential targets were predicted by performing a search in the following online databases: Diana microT4.0 (http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=microrna/home.do) and MIRDB (http://www.microrna.org/microrna/home.do).

Transfections

Cells were cultured to 90% confluence in six-well plates and transfected with 80 nM siRNA or mimic (Ribobio Co., Guangzhou, China). Transfections were performed using 5 μl Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Cells were cultured to 90% confluence in six-well plates and transfected with 80 nM siRNA or mimic (Ribobio Co., Guangzhou, China). Transfections were performed using 5 μl Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA).
mimics and treated with or without 5 ng/ml TGF-β1 for 24 h. Cells were then incubated in 200 μl DMSO (Sigma, St. Louis, MO, USA) for different times. Total RNA was extracted with the TRIzol reagent (Tiangen Biotech, Beijing, China). Reverse transcription was carried out using M-MLV RT (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. Amplification of the cDNA product was performed using GAPDH as an internal control with the Revert Aid First Strand cDNA Synthesis Kit (Thermo Scientific, Thermo Electron Co., MA, USA) and the 7500 software (Applied Biosystems, Foster City, CA, USA). Primer sequences were as follows: NRP2: 5'-CATCTCGGCTTTTGCAGGG-3' (sense), 5'-AGTGCCAGCCACGTCTTG-3' (antisense); GAPDH: 5'-CAAGGTATCCATGACAACTTG-3' (sense), 5'-GTCCACACCCGTGCTGTAG-3' (antisense); miR-196a-3p: 5'-CGGCAACAAGAAACUGCUGAG-3' (sense), 5'-GTCCACCACCCTGTTGCTGTAG-3' (antisense); U6: 5'-GCTTCGGCAGCACATATAUUU-3' (antisense); U6: 5'-GCTTCGGCAGCACATATAUUU-3' (antisense); GAPDH: 5'-CGGCAACAAGAAACUGCUGAG-3' (sense), 5'-GTCCACACCCGTGCTGTAG-3' (antisense); miR-196a-3p: 5'-CGGCAACAAGAAACUGCUGAG-3' (sense), 5'-GTCCACACCCGTGCTGTAG-3' (antisense); U6: 5'-GCTTCGGCAGCACATATAUUU-3' (antisense). PCR conditions for mRNA were as follows: activation, 10 min at 95°C; denaturation, 15 s at 95°C; extension, 60 s at 60°C. For miRNAs, reverse transcription and amplification were performed with the PCR system (LongGene, Hangzhou, China) with U6 small nuclear RNA as an internal control. PCR conditions were as follows: activation, 10 min at 95°C; denaturation, 15 s at 95°C; extension, 60 s at 60°C.

**MTT assay**

Following transfection, 5000 cells were plated in 96-well plates in 10% FBS and stimulated with 5 ng/ml TGF-β for 24 h. Cells were then incubated for 4 h in 20 μl 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution (5 mg/ml MTT powder in phosphate buffer saline (PBS) at 37°C in a humidified atmosphere containing 5% CO2. The MTT solution was removed to incubate the cells in 200 μl DMSO (Sigma, St. Louis, MO, USA). Microplate reader (Thermo Scientific, Thermo Electron Co., MA, USA) was used to determine OD. Absorbance was read at 570 nm.

**Protein extraction and western blot analysis**

Cells were transfected with or without siRNA or mimics and treated with or without 5 ng/ml TGF-β for 48 h. Total proteins were extracted with radioimmune precipitation buffer containing 1% Triton (1% Triton X-100, 1% sodium deoxycholate, 150 mM sodium chloride, 50 mM Tris, pH 7.2, 0.1% sodium dodecyl sulfate (SDS), 5 mM ethyylene diamine tetraacetic acid (EDTA), pH 8.0, supplemented with 5 μg/ml aprotinin, 1 μg/ml pepstatin, 2 μg/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride (PMSF). Total cell extracts were separated by SDS- polyacrylamide gel electrophoresis (PAGE), semidy transferred to a 0.45-μm polyvinylidene fluoride (PVDF) membrane, and incubated overnight with primary antibodies at 4°C. Immunoreactivity was revealed by ChemiScope5200 chemiluminescence imaging system. The primary antibodies of rabbit anti-NRP2, mouse anti-β-actin were purchased from Abcam, Cambridge, MA, USA.

**Invasion and motility assays**

For invasion assays, 1.0 × 10^5 cells were seeded in a Matrigel-coated chamber with 8.0 mm pores (Corning Inc., NY, USA). For motility assays, 5.0 × 10^4 cells were plated on uncoated membranes with 8.0 mm pores (Corning Inc.). Cells were seeded in serum-free medium and translocated toward complete growth medium for 24 h.

**Luciferase reporter assays**

The MDA-MB-231 cells were seeded onto 24-well plates (5.0 × 10^4 cells/well) and allowed to adhere overnight. The following day, the cells were transiently transfected using transfection reagent using Lipofectamine 2000 reagent (Invitrogen) with pGL3–X-baI (Promega) and 100 ng/well psi-Check2 luciferase reporter (Promega) that housed the 3′UTR sequence that contained either a wild-type or mutant version of the NRP2 seed sequence and transfected into MDA-MB-231 cells in the presence of a miR-196a-3p mimic or its control. The Renilla luciferase activities were measured by the Luciferase Reporter System (Promega, Madison, WI, USA) at 2 days after transfection.

**Tumor development and growth assays in vivo**

Twenty athymic nude mice (Model Animal Research Center of Nanjing University, Nanjing, China), 4–6 weeks old, were randomly assigned into groups. MDA-MB-231 cells (5 × 10^6) were injected into the right mammary fat pad in situ. When the xenograft tumors formed by the MDA-MB-231 cells reached 50 mm^3, miR-196a-3p and control agomir (1 nmol/injection, three times per week) were injected into the tumors. Tumor volume was calculated as 0.5 × x^2 × y where x is the tumor width and y is the tumor length. After the last in vivo optical imaging, all mice were sacrificed for further analysis. All experimental protocols were approved by the Institutional Animal Care and Use Committee of Soochow University.
Metastasis assays in nude mice

MDA-MB-231 cells (1 × 10^6) were injected into the tail vein of athymic nude mice. miR-196a-3p and control agomir were injected (5 nmol/injection, three times per week). Mice became moribund and were sacrificed after pulmonary perfusion 4 weeks later. The number of tumor nodules formed on the lung surface was counted. Lungs were excised and fixed in 10% formaldehyde, after which 0.2 mm paraffin-embedded sections were prepared and stained with hematoxylin and eosin.

Immunostaining

For NRP2 immunostaining of human primary tumors, freshly frozen samples of human primary breast tumors were sectioned, fixed in acetone, and immunostained with anti-NRP2 antibody, anti Ki-67 antibody (Abcam, Cambridge, MA, USA). The samples were incubated in biotinylated anti-rabbit secondary antibody (Beyotime, Shanghai, China) followed by 3,3′-diaminobenzidine tetrahydrochloride (DAB) (Beyotime). The slides were counterstained with hematoxylin.

Statistical analyses

The software, SPSS Version 16.0 for Windows (SPSS Inc, Chicago, IL, USA), was used for analysis. The Student’s t test and chi-square test were used for comparisons.

Survival curves were plotted by the Kaplan–Meier method and compared by the log-rank test. The survival data were evaluated by univariate and multivariate Cox regression. Differences were considered significant when \( P < 0.05 \).

CONCLUSION

In summary, we showed that miR-196a-3p is stimulated by TGF-β1 and contributes to cell metastasis by targeting NRP2 in breast cancer. miR-196a-3p is expressed at low levels in breast cancer tissues, and prevent the expression of miR-196a-3p was significantly associated with the progression of breast cancer. The TGF-β1/miR-196a-3p/NRP2 axis could provide further insight into the pathogenesis of breast cancer, and miR-196a-3p might be a potential diagnostic and therapeutic target for the metastasis of breast cancer.

ACKNOWLEDGMENTS AND FUNDING

This study was supported by Jiangsu Provincial Commission of Health and Family Planning (H201517), the Chinese Nature Science Foundation (81272738, 81372867, 81472297) and the A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions. We would like to thank the Affiliated Hospital of Soochow University for providing us with the tumor specimens.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66:7-30.
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66:115-132.
3. Zarzynska JM. Two faces of TGF-beta1 in breast cancer. Mediators of inflammation. 2014; 2014:141747.
4. Wang J, Shao N, Ding X, Tan B, Song Q, Wang N, Jia Y, Ling H, Cheng Y. Crosstalk between transforming growth factor-beta signaling pathway and long non-coding RNAs in cancer. Cancer letters. 2016; 370:296-301.
5. Massague J. TGFbeta in Cancer. Cell. 2008; 134:215-230.
6. Zu X, Zhang Q, Cao R, Liu J, Zhong J, Wen G, Cao D. Transforming growth factor-beta signaling in tumor initiation, progression and therapy in breast cancer: an update. Cell and tissue research. 2012; 347:73-84.
7. Connolly EC, Freimuth J, Akhurst RJ. Complexities of TGF-beta targeted cancer therapy. Int J Biol Sci. 2012; 8:964-978.
8. Sun MM, Li JF, Guo LL, Xiao HT, Dong L, Wang F, Huang FB, Cao D, Qin T, Yin XY, Li J, Wang SL. TGF-beta1 suppression of microRNA-450b-5p expression: a novel mechanism for blocking myogenic differentiation of rhabdomyosarcoma. Oncogene. 2014; 33:2075-2086.
9. Sun M, Huang F, Yu D, Zhang Y, Xu H, Zhang L, Li L, Dong L, Guo L, Wang S. Autoregulatory loop between TGF-beta1/miR-411-5p/SPRY4 and MAPK pathway in rhabdomyosarcoma modulates proliferation and differentiation. Cell death & disease. 2015; 6:1e1859.
10. Chen W, Zhou S, Mao L, Zhang H, Sun D, Zhang J, Li J, Tang JH. Crosstalk between TGF-beta signaling and miRNAs in breast cancer metastasis. Tumour biology. 2016; 37:10011-10019.
11. Johansson J, Berg T, Kurzejamska E, Pang MF, Tabor V, Jansson M, Roswall P, Pietras K, Sund M, Religa P, Fuxe J. MiR-155-mediated loss of C/EBPbeta shifts the TGF-beta response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer. Oncogene. 2013; 32:5614-5624.
12. Li Y, Li W, Ying Z, Tian H, Zhu X, Li J, Li M. Metastatic heterogeneity of breast cancer cells is associated with expression of a heterogeneous TGFbeta-activating miR424-503 gene cluster. Cancer research. 2014; 74:6107-6118.
13. Yin K, Yin W, Wang Y, Zhou L, Liu Y, Yang G, Wang J, Lu J. MiR-206 suppresses epithelial mesenchymal transition by targeting TGF-beta signaling in estrogen receptor positive breast cancer cells. Oncotarget. 2016; 7:24537-24548. doi: 10.18632/oncotarget.8233.

14. Liu HT, Gao P. The roles of microRNAs related with progression and metastasis in human cancers. Tumour biology. 2016; doi:10.1007/s13277-016-5436-9. [Epub ahead of print].

15. Ganju A, Khan S, Hafeez BB, Behrmann SW, Yallapu MM, Chauhan SC, Jaggi M. miRNA nanotherapeutics for cancer. Drug discovery today. 2016; doi:10.1016/j.drudis-016-10-014. [Epub ahead of print].

16. Parvani JG, Taylor MA, Schiemann WP. Noncanonical TGF-beta signaling during mammary tumorigenesis. J Mammary Gland Biol Neoplasia. 2011; 16:127-146.

17. Taylor MA, Parvani JG, Schiemann WP. The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia. 2010; 15:169-190.

18. Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res. 2009; 19:128-139.

19. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60:277-300.

20. Maruthanila VL, Elancheran R, Kunnumakkara AB, Kabilan S, Kotoky J. Recent development of targeted approaches for the treatment of breast cancer. Breast Cancer. 2016; doi:10.1007/s12282-016-0732-1. [Epub ahead of print]

21. Peng F, Xiong L, Tang H, Peng C, Chen J. Regulation of epithelial-mesenchymal transition through microRNAs: clinical and biological significance of microRNAs in breast cancer. Tumour biology. 2016; doi:10.1007/s13277-016-5334-1. [Epub ahead of print]

22. De Leeneer K, Claes K. Non Coding RNA Molecules as Potential Biomarkers in Breast Cancer. Advances in experimental medicine and biology. 2015; 867:263-275.

23. Maris P, Blomme A, Palacios AP, Costanza B, Bellahcene A, Bianchi E, Gofflot S, Drion P, Trombino GE, Di Valentin E, Cusumano PG, Maweja S, Jerusalem G, et al. Asporin is a Fibroblast-Derived TGF-beta1 Inhibitor and a Tumor Suppressor Associated with Good Prognosis in Breast Cancer. PLoS medicine. 2015; 12:e1001871.

24. Guo L, Zhang Y, Zhang L, Huang F, Li J, Wang S. MicroRNAs, TGF-beta signaling, and the inflammatory microenvironment in cancer. Tumour biology. 2016; 37:115-125.

25. Yasuoka H, Kodama R, Tsujimoto M, Yoshidome K, Akamatsu H, Nakahara M, Inagaki M, Sanke T, Nakamura Y. Neuropilin-2 expression in breast cancer: correlation with lymph node metastasis, poor prognosis, and regulation of CXCR4 expression. BMC Cancer. 2009; 9:220.

26. Fung TM, Ng KY, Tong M, Chen JN, Chai S, Chan KT, Law S, Lee NP, Choi MY, Li B, Cheung AL, Tsao SW, Qin YR, et al. Neuropilin-2 promotes tumourigenicity and metastasis in oesophageal squamous cell carcinoma through ERK-MAPK-ETV4-MMP-E-cadherin deregulation. The Journal of pathology. 2016; 239:309-319.

27. Moriarty WF, Kim E, Gerber SA, Hammers H, Alani RM. Neuropilin-2 promotes melanoma growth and progression in vivo. Melanoma research. 2016; 26:321-328.

28. Jung H, Kim B, Moon BI, Oh ES. Cytokeratin 18 is necessary for initiation of TGF-beta1-induced epithelial-mesenchymal transition in breast epithelial cells. Molecular and cellular biochemistry. 2016; 423:21-28.

29. Wendt MK, Allington TM, Schiemann WP. Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Future Oncol. 2009; 5:1145-1168.

30. Hoshino Y, Katsuno Y, Ehata S, Miyazono K. Autocrine TGF-beta protects breast cancer cells from apoptosis through reduction of BH3-only protein. Bim. Journal of biochemistry. 2011; 149:55-65.

31. Bierie B, Stover DG, Abel TW, Chytli A, Gorska AE, Aakre M, Forrester E, Yang L, Wagner KU, Moses HL. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. Cancer research. 2008; 68:1809-1819.

32. Lu YC, Chang JT, Liao CT, Kang CJ, Huang SF, Chen IH, Huang CC, Huang YC, Chen WH, Tsai CY, Wang HM, Yen TC, You GR, et al. OncomiR-196 promotes an invasive phenotype in oral cancer through the NME4-JNK-TIMP1-MMP signaling pathway. Mol Cancer. 2014; 13:218.

33. Yuan J, Anbalagan D, Lee LH, Samy RP, Shanmugam MK, Kumar AP, Sethi G, Lobie PE, Lim LH. ANXA1 inhibits miRNA-196a in a negative feedback loop through NF-kB and c-Myc to reduce breast cancer proliferation. Oncotarget. 2016; 7:27007-27020. doi: 10.18632/oncotarget.8875.

34. Lu YC, Chang JT, Chan EC, Chao YK, Yeh TS, Chen JS, Cheng AJ. miR-196, an Emerging Cancer Biomarker for Digestive Tract Cancers. J Cancer. 2016; 7:650-655.

35. De Leeneer K, Claes K. Non Coding RNA Molecules as Potential Biomarkers in Breast Cancer. Advances in experimental medicine and biology. 2015; 867:263-275.

36. Maris P, Blomme A, Palacios AP, Costanza B, Bellahcene A, Bianchi E, Gofflot S, Drion P, Trombino GE, Di Valentin E, Cusumano PG, Maweja S, Jerusalem G, et al. Asporin is a Fibroblast-Derived TGF-beta1 Inhibitor and a Tumor Suppressor Associated with Good Prognosis in Breast Cancer. PLoS medicine. 2015; 12:e1001871.

37. Guo L, Zhang Y, Zhang L, Huang F, Li J, Wang S. MicroRNAs, TGF-beta signaling, and the inflammatory microenvironment in cancer. Tumour biology. 2016; 37:115-125.

38. Yasuoka H, Kodama R, Tsujimoto M, Yoshidome K, Akamatsu H, Nakahara M, Inagaki M, Sanke T, Nakamura Y. Neuropilin-2 expression in breast cancer: correlation with lymph node metastasis, poor prognosis, and regulation of CXCR4 expression. BMC Cancer. 2009; 9:220.